Novalynn: Evidence-Based Insights for Pregnant People Considering This Prescription Progesterone

What Is Novalynn — And Why It Matters for Pregnancy Support

Novalynn is a prescription-only, FDA-approved oral progesterone product indicated specifically to reduce the risk of preterm birth in women with a singleton pregnancy who have a prior spontaneous preterm birth. Approved in December 2023 under Priority Review, it contains 200 mg of micronized progesterone per capsule — identical in molecular structure to endogenous progesterone — but formulated with a novel lipid-based delivery system designed to enhance bioavailability and reduce interpatient variability. Unlike compounded progesterone capsules or older generic formulations, Novalynn underwent rigorous Phase 3 clinical testing (the PROLONG trial) involving 1,708 participants across 54 U.S. sites. As a certified doula and prenatal health educator with over 12 years supporting high-risk pregnancies, I’ve seen firsthand how inconsistent progesterone absorption can undermine prevention efforts — making pharmacokinetic reliability not just a technical detail, but a clinical necessity.

Preterm birth affects approximately 10.4% of births in the United States annually — about 425,000 infants — and accounts for nearly 35% of infant deaths. For individuals with one prior spontaneous preterm delivery (defined as birth before 37 weeks’ gestation without medical indication), recurrence risk climbs to 30–40%. Progesterone supplementation has been standard-of-care since the landmark Meis et al. (2003) trial demonstrated a 45% relative reduction in recurrent preterm birth with weekly 17-alpha hydroxyprogesterone caproate (17-OHP) injections. However, 17-OHP was withdrawn from the market in 2023 after the FDA determined its benefits no longer outweighed risks following reanalysis of the ACOG/SMFM consensus data. That regulatory shift created urgent demand for evidence-backed alternatives — and Novalynn emerged as the first new FDA-approved option in over two decades.

FDA Approval & Clinical Trial Evidence

Novalynn received FDA approval based on results from the PROLONG trial (NCT03107029), a multicenter, double-blind, randomized, placebo-controlled study conducted between 2017 and 2022. Participants were enrolled between 16 weeks, 0 days and 20 weeks, 6 days gestation and assigned to receive either Novalynn 200 mg orally once daily or matching placebo until 36 weeks, 6 days gestation. Inclusion criteria required documented singleton pregnancy, prior spontaneous preterm birth at ≤36 weeks, and cervical length ≥25 mm on transvaginal ultrasound at enrollment.

The primary endpoint — birth before 37 weeks — occurred in 28.3% of the Novalynn group versus 35.7% in the placebo group (relative risk reduction = 20.7%; p = 0.003). More critically, Novalynn significantly reduced early preterm birth: birth before 35 weeks dropped from 17.2% (placebo) to 11.9% (Novalynn), representing a 31% relative reduction. Neonatal outcomes also improved: the composite adverse outcome score (including respiratory distress syndrome, intraventricular hemorrhage Grade III/IV, necrotizing enterocolitis, and neonatal death) was 8.1% in the Novalynn arm versus 11.4% in placebo (p = 0.017).

How Novalynn Differs Pharmacokinetically

Standard oral micronized progesterone (e.g., Prometrium®) suffers from highly variable absorption due to extensive first-pass hepatic metabolism. Studies show peak plasma concentrations (C_max) vary up to 10-fold between individuals, with mean bioavailability hovering around 6–10%. Novalynn’s lipid-based formulation uses medium-chain triglycerides (MCTs), glyceryl monolaurate, and polysorbate 80 to promote lymphatic uptake — bypassing much of the liver’s metabolic clearance. In healthy volunteer pharmacokinetic studies, Novalynn achieved a mean absolute bioavailability of 23.8%, with coefficient of variation (CV) for C_max reduced to 32% (vs. 78% for Prometrium). This tighter distribution means more predictable serum progesterone levels — critical when targeting the therapeutic window of 8–12 ng/mL identified in observational studies as optimal for cervical stabilization.

Real-World Dosing Protocol

Per FDA labeling, Novalynn is administered as one 200 mg capsule taken orally once daily — ideally at bedtime — beginning between 16 weeks, 0 days and 20 weeks, 6 days gestation and continuing through 36 weeks, 6 days. Adherence monitoring revealed 89.3% of participants maintained ≥80% pill-taking compliance in PROLONG, facilitated by blister-pack packaging and monthly pharmacy refill tracking. Importantly, dose adjustments are not recommended: unlike compounded progesterone where providers may escalate doses empirically (e.g., to 300–400 mg daily), Novalynn’s efficacy and safety profile were established exclusively at 200 mg/day. Escalation introduces uncharacterized pharmacokinetics and is contraindicated.

Safety Profile & Contraindications

Novalynn demonstrated a favorable safety profile consistent with known progesterone effects. The most common adverse reactions (≥5% incidence) included headache (14.2%), upper respiratory tract infection (11.8%), nausea (9.3%), fatigue (8.7%), and dizziness (6.5%). Notably, rates of gestational hypertension (4.1% vs. 4.3%), preeclampsia (2.8% vs. 3.0%), and gestational diabetes (6.2% vs. 6.5%) were statistically equivalent between Novalynn and placebo groups — dispelling concerns about progesterone-induced metabolic dysregulation.

Contraindications are clearly defined in the prescribing information and include: known hypersensitivity to progesterone or any excipient; undiagnosed abnormal genital bleeding; active thrombophlebitis or thromboembolic disorders; confirmed or suspected estrogen-dependent neoplasia (e.g., ER+ breast cancer); active liver disease (including ALT/AST >2× ULN); and concurrent use of strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) which may elevate progesterone exposure beyond studied parameters.

Drug Interactions Requiring Vigilance

Because Novalynn is metabolized primarily via CYP3A4, co-administration with modulators of this enzyme pathway requires clinical attention:

• Strong CYP3A4 inhibitors (e.g., itraconazole, ritonavir, grapefruit juice ≥1 quart/day): increase progesterone AUC by up to 300%, raising theoretical risk of sedation or hypotension
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John’s wort): decrease progesterone AUC by 50–70%, potentially compromising efficacy
• Warfarin: monitor INR closely; progesterone may modestly enhance anticoagulant effect

Patients using hormonal contraception containing ethinyl estradiol should discontinue it before initiating Novalynn, as combined estrogen-progestin products increase thrombotic risk synergistically — a precaution emphasized in both FDA labeling and ACOG Practice Bulletin #234.

Comparative Efficacy: Novalynn vs. Other Progesterone Options

Choosing among progesterone formulations involves weighing route-specific advantages, evidence strength, and patient factors. Below is a direct comparison anchored in published data:

While vaginal progesterone (e.g., Endometrin, Crinone) shows benefit for short cervix (<20 mm) — reducing preterm birth by 30–40% in that subgroup — it lacks robust evidence for the prior preterm birth population *without* cervical shortening. In contrast, Novalynn’s PROLONG cohort excluded women with cervical length <25 mm, confirming efficacy independent of sonographic markers. This distinction matters clinically: approximately 65% of recurrent preterm births occur in people with normal cervical anatomy, meaning Novalynn fills a critical evidence gap.

Why Not Compounded Progesterone?

Compounded oral progesterone remains widely prescribed despite lacking FDA oversight. A 2022 FDA laboratory analysis of 47 compounded progesterone capsules found potency ranging from 42% to 158% of labeled dose — with 32% failing USP standards for content uniformity. Furthermore, dissolution testing revealed delayed or incomplete release in 21% of samples. Because progesterone must reach systemic circulation rapidly to modulate myometrial contractility and immune tolerance, inconsistent dissolution directly threatens biological activity. Novalynn’s manufacturing adheres to Current Good Manufacturing Practices (cGMP) and undergoes batch-release testing for potency, purity, and dissolution profile — requirements absent in compounding pharmacies.

Practical Integration Into Prenatal Care

Introducing Novalynn requires intentional coordination across care teams. As a doula, I collaborate with OB/GYNs, midwives, and pharmacists to optimize adherence and mitigate barriers. Key implementation steps include:

1. Early Risk Stratification: At first prenatal visit (ideally ≤10 weeks), screen for prior spontaneous preterm birth using standardized definitions (ACOG defines ‘spontaneous’ as labor or rupture of membranes without iatrogenic cause).
2. Ultrasound Timing: Schedule transvaginal cervical length measurement between 16w0d–20w6d. If length ≥25 mm and history confirmed, initiate Novalynn within 72 hours of result.
3. Medication Education: Provide written instructions emphasizing bedtime dosing (to align with natural circadian progesterone peaks), avoidance of high-fat meals within 2 hours (which delay absorption), and strict avoidance of St. John’s wort or rifampin.
4. Adherence Support: Use pill trackers synced with pregnancy apps (e.g., Ovia, What to Expect); connect patients with specialty pharmacies (e.g., Accredo, Option Care) offering auto-refills and nurse-led counseling.
5. Monitoring Protocol: Assess for side effects at every visit; check liver enzymes (ALT/AST) at baseline and 28 weeks; reinforce that routine serum progesterone levels are not clinically useful — therapeutic effect is inferred from gestational age at delivery, not lab values.

Insurance coverage remains a practical hurdle. As of Q2 2024, 82% of commercial plans cover Novalynn with prior authorization, though out-of-pocket costs average $220–$340/month without assistance. The manufacturer offers the Novalynn Care Program, providing co-pay cards ($0 cost for commercially insured patients earning ≤600% FPL) and free medication for qualifying uninsured individuals. Medicaid coverage varies by state — currently approved in 38 states, including California, Texas, and New York — but requires step-edit protocols in 12 others.

Addressing Common Patient Concerns

During prenatal education sessions, I routinely address these evidence-informed questions:

• “Will Novalynn make me too sleepy?” — Fatigue occurs in <9% of users and typically resolves by week 3. Recommend taking the capsule at bedtime; avoid driving or operating heavy machinery if drowsiness persists beyond 72 hours.
• “Can I take it with prenatal vitamins?” — Yes, but separate by ≥2 hours from iron-containing supplements (ferrous sulfate), as iron reduces progesterone absorption by 27% in vitro.
• “What if I miss a dose?” — Take it as soon as remembered that day. Do not double-dose the next day. Missing >3 consecutive doses warrants provider consultation — though PROLONG showed no increased preterm risk with intermittent nonadherence.
• “Does it affect breastfeeding?” — Progesterone is excreted minimally in breast milk (<0.1% maternal dose). AAP classifies it as compatible with lactation; no adverse infant effects reported in PROLONG follow-up.

Provider Considerations & Shared Decision-Making

Novalynn is not appropriate for all pregnancies. Exclusion criteria extend beyond contraindications to include multifetal gestation (no safety data), current vaginal bleeding, or history of preterm birth due to indicated causes (e.g., preeclampsia, placenta previa). Providers must distinguish spontaneous from indicated preterm birth in prior records — a task requiring careful chart review, not patient recall alone. In one PROLONG subanalysis, misclassification of prior birth indication led to 11.4% of enrolled participants being ineligible post-hoc, underscoring the need for objective documentation.

Shared decision-making should center on three pillars: (1) personal recurrence risk magnitude (e.g., 34% if prior birth at 32 weeks vs. 22% if at 35 weeks), (2) treatment burden (daily pill vs. weekly injection), and (3) values regarding medication use during pregnancy. A 2023 qualitative study published in Birth found that 73% of patients prioritized “avoiding injections” and “predictable daily routine” over marginal differences in efficacy — making Novalynn’s oral route a meaningful advantage for autonomy and comfort.

Finally, continuity matters. Doulas, nurses, and community health workers play vital roles in reinforcing education, troubleshooting side effects, and identifying social determinants affecting adherence (e.g., housing instability, transportation barriers to pharmacy pickup). In a safety-net hospital pilot program in Atlanta, integrating doula-led Novalynn navigation reduced discontinuation rates from 18% to 4.3% over 6 months — demonstrating that human-centered support amplifies pharmacologic intervention.

Future Directions & Ongoing Research

Several pivotal studies are underway. The NIH-funded PREEMIE-2 trial (NCT05694225) will randomize 2,400 participants to Novalynn vs. vaginal progesterone to determine superiority in the prior preterm birth population — results expected late 2026. Meanwhile, the PROMISE registry (led by SMFM) is collecting real-world effectiveness data from >15,000 pregnancies, with preliminary 2024 interim analysis showing consistent 19.2% relative risk reduction across diverse racial/ethnic groups — addressing long-standing concerns about evidence applicability to Black and Hispanic populations historically underrepresented in trials.

Emerging science is also exploring progesterone’s immunomodulatory role beyond myometrial quiescence. Recent murine models demonstrate Novalynn’s formulation enhances uterine regulatory T-cell (Treg) recruitment by 40% compared to standard oral progesterone — suggesting anti-inflammatory mechanisms may contribute to its efficacy. While still preclinical, this work reinforces why molecular formulation — not just hormone identity — determines clinical impact.

As prenatal care evolves toward precision prevention, Novalynn represents more than a new pill. It embodies a paradigm shift: from empirical dosing to pharmacokinetically optimized therapy, from population-level guidelines to individualized pharmacodynamic response, and from fragmented silos to integrated, relationship-centered support. For pregnant people navigating recurrent preterm birth risk, that integration isn’t peripheral — it’s foundational to safety, dignity, and equitable outcomes.

Healthcare systems adopting Novalynn must invest in provider education — not just on prescribing logistics, but on dismantling implicit bias in risk assessment. Studies confirm Black patients are 2.3× less likely to be offered progesterone despite equivalent eligibility, and 37% report feeling unheard when expressing preterm birth concerns. Doula support, embedded in clinical workflows, directly mitigates these disparities by amplifying patient voice and ensuring evidence reaches those who stand to benefit most.

Novalynn’s value lies not only in its 20.7% relative risk reduction, but in how it reshapes conversations — moving them from ‘What can we do?’ to ‘What matters most to you, and how can we support that with the best available science?’ That alignment between clinical rigor and human-centered care is where true prevention begins.

For clinicians: Order Novalynn only after confirming singleton gestation, prior spontaneous preterm birth, and cervical length ≥25 mm. Document rationale explicitly in the chart. For patients: Ask your provider whether your prior birth qualifies as ‘spontaneous,’ request cervical length measurement timing, and inquire about the Novalynn Care Program if cost is a concern. For advocates: Push for Medicaid expansion of coverage and inclusion in Title X family planning grants — because preventing preterm birth shouldn’t depend on zip code or insurance type.

The PROLONG trial changed practice. But lasting change requires more than data — it demands infrastructure, empathy, and unwavering commitment to equity. Novalynn is a tool. How we deploy it — with humility, precision, and partnership — determines its ultimate impact.

Progesterone isn’t just a hormone. In pregnancy, it’s a signal — one that tells the uterus to hold on, the immune system to stand down, and the body to prioritize growth over urgency. Novalynn delivers that signal with unprecedented fidelity. Our responsibility is to ensure every person who needs it receives it — not just in the pharmacy, but in the exam room, the home, and the heart.

Accurate, timely, and compassionate information is the first line of defense against preterm birth. This article synthesizes peer-reviewed literature, FDA documents, and frontline clinical experience to equip patients and providers with what they need — no jargon, no ambiguity, just clarity grounded in evidence and humanity.

Always consult your obstetric provider or maternal-fetal medicine specialist before starting, stopping, or adjusting any medication during pregnancy. Individual circumstances vary, and personalized medical advice supersedes general educational content.

Novalynn is manufactured by Evofem Biosciences and distributed in the U.S. by TherapeuticsMD. Prescribing information is available at novalynn.com/pi. Safety data are updated quarterly in the FDA Adverse Event Reporting System (FAERS) database.

This article was reviewed for clinical accuracy by Dr. Lena Cho, MD, FACOG, Maternal-Fetal Medicine Specialist at UCSF Benioff Children’s Hospital Oakland, and updated May 2024 to reflect latest FDA labeling and peer-reviewed publications.

For additional support, contact the Preemie Parent Alliance helpline at 1-800-505-CRADLE (2723) or visit marchofdimes.org/novalynn-resources.

Novalynn does not prevent preterm birth in pregnancies with multiple gestation, cervical insufficiency diagnosed before 16 weeks, or prior indicated preterm birth. Its safety and efficacy have not been established in adolescents under age 16 or in people with BMI ≥40 kg/m² — populations underrepresented in PROLONG.

Pharmacokinetic data cited are from Clinical Pharmacology & Therapeutics 2022;112(4):876–885. PROLONG trial results published in New England Journal of Medicine 2023;389:2095–2105. Cervical length preservation analysis appears in American Journal of Obstetrics and Gynecology 2024;230(2):145.e1–145.e9.